1-10 of about 52 Results
Sory by:

1-10 of about 52 Results



  • All
  • Biological Testing
  • Clinical Pharmacology & Modeling
  • Discovery
  • Histology
  • Laboratory Science
  • Pathology
  • Research Models
  • Safety Assessment
  • Toxicology

Stereology: Probing for Precision


Stereology is a tool for obtaining unbiased estimates of object numbers and/or sizes within three-dimensional regions of interest.  For biological samples, quantitative measurements are potentially more objective and accurate when compared to traditional semi-quantitative grading of findings by pathologists (i.e., scoring of morphologic changes as minimal, mild, moderate, or severe).  Although both approaches require high […]

Immunostaining Assay Optimization – Tackling Intrinsic Study Variables


Immunohistochemistry or Immunofluorescence (IHC/IF) is employed routinely for investigative and diagnostic evaluations of antigen-antibody interactions within cells or tissues. While most IHC/IF target antigens are proteins, other antigenic biological substrates can also be recognized by antibodies (e.g., carbohydrates, lipids, or nucleic acids). Accurate and reproducible results are achieved when procedures used to identify and localize […]

How to Ensure the Quickest Possible Histology Project Timeline


With the processing of up to 50,000 tissues per month, and projects regularly flowing in and out of our labs, histology scheduling at EPL is a continual process. Recognizing that the project timeline, in addition to quality and expertise, is one of the most important factors to our clients, we’re providing the following tips on the items […]

Pathology Peer Review


Experimental Pathology Laboratories, Inc. (EPL) meets or exceeds current FDA guidelines following the release of “Pathology Peer Review in Nonclinical Studies: Questions and Answers, Guidance for Industry” document in December 2021

Meet EPL and Aclairo at the 38th Annual ACT in Booth #200


Meet EPL and Aclairo at the 38th Annual ACT in Booth #200 Members of EPL, Inc. and Aclairo Pharmaceutical Development Group, Inc. will attend the 2017 38th Annual meeting of the American College of Toxicology held at the Palm Springs Convention Center – 277 N. Avenida Caballeros –Palm Springs, CA 92262.  Register for ACT Join EPL at Our Hosted Program: “All About […]

Meet EPL and Aclairo at the SOT 57th Annual Meeting


Meet the professionals from EPL and Aclairo at the SOT 57th Annual Meeting and ToxExpo in San Antonio, Texas from March 11-15 in Booth #922. Register Now About EPLFounded in 1971, Experimental Pathology Laboratories, Inc. (EPL®) is a private, employee-owned U.S. company that is recognized internationally for its ability to meet the needs of the scientific community and the […]

Experimental Pathology Laboratories, Inc. Announces a Strategic Alliance with Quality Scientific Solutions, LLC


Experimental Pathology Laboratories, Inc. (EPL) announces a new strategic alliance with Quality Scientific Solutions, LLC (QS3). This alliance is targeted to provide EPL’s preclinical pathology expertise as an important resource to QS3. About Quality Scientific SolutionsQuality Scientific Solutions, LLC is a research and consulting company dedicated to helping clients create products that meet the highest standard […]

EPL – Independent and Employee-Owned


Experimental Pathology Laboratories, Inc. (EPL) is an independent, private, employee-owned company that is recognized internationally for its ability to meet the needs of the scientific community and the challenges of preclinical safety testing and development with high quality histopathology services.  EPL was founded in 1971, and became an employee-owned company in 1992.  EPL is proud […]

Aclairo Welcomes Dr. Heath Thomas as New President


Experimental Pathology Laboratories, Inc. (EPL) and Aclairo Pharmaceutical Development Group, Inc. (Aclairo) are excited to announce that Dr. Heath Thomas has joined Aclairo as President and Senior Consultant. Dr. Thomas is a board-certified veterinary pathologist with over 20 years of experience in drug development from time spent with SmithKline Beecham, DuPont Pharmaceuticals, and GlaxoSmithKline, as […]

Use of Exposure-Response (ER) Modeling of QTc Data – A Movement Away from a Thorough QT Study


Since 2005 the US Food and Drug Administration (FDA) has required the evaluation of a new molecular entity in a thorough QT (TQT) study, which is intended to determine a drug’s effect on the QT interval.  The QT interval represents the duration of ventricular depolarization and subsequent cardiac repolarization, measured from the beginning of the […]

1 2 3 6